Biomaterial Database

Dopaminergic Therapy for Restless Legs Syndrome/Willis-Ekbom Disease. 2015

Rochelle S Zak, and Arthur S Walters

Sleep Disorders Center, University of California San Francisco, 2330 Post Street, San Francisco, CA 94115, USA. Electronic address: Rochelle.Zak@ucsf.edu.

Dopaminergic therapies have been a mainstay of restless legs treatment and are endorsed as first-line therapies by multiple professional societies. This article summarizes the differences and similarities among the dopamine agonists with attention to pharmacology, efficacy, side effects, and dosing.

UI	MeSH Term	Description	Entries
D012148	Restless Legs Syndrome	A disorder characterized by aching or burning sensations in the lower and rarely the upper extremities that occur prior to sleep or may awaken the patient from sleep.	Restless Leg Syndrome,Restless Legs,Willis Ekbom Disease,Willis Ekbom Syndrome,Willis-Ekbom Disease,Willis-Ekbom Syndrome,Wittmaack Ekbom Syndrome,Wittmaack-Ekbom Syndrome,Disease, Willis Ekbom,Disease, Willis-Ekbom,Syndrome, Restless Leg,Syndrome, Willis Ekbom,Syndrome, Willis-Ekbom,Syndrome, Wittmaack Ekbom,Syndrome, Wittmaack-Ekbom
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D018491	Dopamine Agonists	Drugs that bind to and activate dopamine receptors.	Dopamine Receptor Agonists,Dopaminergic Agonists,Agonists, Dopamine Receptor,Agonists, Dopaminergic,Dopamine Agonist,Dopamine Receptor Agonist,Dopaminergic Agonist,Receptor Agonists, Dopamine,Agonist, Dopamine,Agonist, Dopamine Receptor,Agonist, Dopaminergic,Agonists, Dopamine,Receptor Agonist, Dopamine